First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study will assess efficacy (based on response rate) and safety (based on grade ≥ 3
severe adverse effects) of the combination Gemcitabine Cisplatin (GC) + anti-PD-L1 (avelumab)
in first-line treatment for locally advanced or metastatic urothelial bladder cancer
patients, after 6 cycles of treatment (or at 18 weeks if less than 6 cycles have been given,
or earlier if a second line treatment is needed, before this new anticancer treatment has
been started).